Logo

Opaldia to Offer DiaGenic's Gene Expression Tests in UK

Dec 14, 2007
NEW YORK (GenomeWeb News) – Opaldia will distribute DiaGenic’s breast cancer blood test in the UK and will use a research-use-only version of the test in its own studies until the test receives the CE Mark for use in Europe.
 
Opaldia will offer the gene expression test to UK patients under its Breastcare Program. The firm already offers Agendia’s MammaPrint, which is used in disease prognosis, and Agendia's CupPrint, which identifies the origin of metastasized tumors.
 
Diagenic hopes to receive the CE Mark for the breast cancer test by the end of 2008.
 

Breaking News
The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.